.Nature Medicine, Released online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin resulted in boosted progression-free as well as total survival, triggering FDA approval and a brand-new treatment choice for people.